Several significant and positive changes with respect to adherence, adherence interventions, adherence technologies, and medication monitors in particular were included in the newly released WHO 2017 Update on Guidelines for DS-TB Treatment. These guidelines make several important points about the importance of TB treatment adherence, about the impact of various adherence interventions, and about the promising role of digital technologies in achieving improved treatment outcomes and reduced disease morbidity. Importantly, the guidelines contain the first-ever WHO evidence-based recommendations on the use of, among other approaches, digital medication monitors to help patients adhere to TB medication and deliver TB care. These guidelines and new recommendations represent a significant and positive step forward with respect to adherence interventions generally — acknowledging that some form of adherence intervention is, in essence, required in order to ensure good TB treatment outcomes. In addition, these guidelines make clear that that digital medication monitors such as the evriMED devices (www.wisepill.com) developed with support from the Bill & Melinda Gates Foundation, have been “approved for use” pursuant to these new guidelines.